Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Berberine and Tamoxifen Interaction: Avoid | Peptide Database

Compound Profiles Berberine Plant Alkaloid | Natural Glucose & Lipid Management Berberine's primary mechanism of action involves activation of AMP-activated protein kinase (AMPK), the cell's master energy-sensing enzyme. Unlike metformin, which activates AMPK

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Berberine

Plant Alkaloid | Natural Glucose & Lipid Management

Berberine's primary mechanism of action involves activation of AMP-activated protein kinase (AMPK), the cell's master energy-sensing enzyme. Unlike metformin, which activates AMPK primarily through inhibition of mitochondrial Complex I, berberine appears to activate AMPK through multiple pathways, including direct inhibition of mitochondrial Complex I, stimulation of AMPK phosphorylation, and modulation of the AMP-to-ATP ratio.

Tamoxifen

Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment

Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Berberine with Tamoxifen?

Combining Berberine with Tamoxifen is not recommended. Both Berberine and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Berberine and Tamoxifen safe together?

This combination carries significant risk. Both Berberine and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Berberine and Tamoxifen?

Both Berberine and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Berberine and Tamoxifen?

Berberine has a half-life of ~4 hours and Tamoxifen has a half-life of ~5-7 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Ovagen — share findings, ask questions, and learn from real experiences Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects. Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.

Source: peptide-db.com ↗

Community Research

Join others researching Kisspeptin — share findings, ask questions, and learn from real experiences Kisspeptin acts as a master regulator of the reproductive system, stimulating GnRH neurons essential for puberty, fertility, and reproductive function. Binds to GPR54/KISS1R receptors on hypothalamic GnRH neurons, triggering pulsatile GnRH release, which stimulates pituitary LH/FSH secretion and gonadal steroid production.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Telmisartan is administered exclusively via the oral route as a tablet. It reaches peak plasma concentration approximately 0.5-1 hour after administration, with absolute bioavailability of approximately 42-58% (dose-dependent). The drug is highly lipophilic, extensively protein-bound (>99.5%), and has a large volume of distribution (~500 L), contributing to its long duration of action. Telmisartan undergoes hepatic glucuronidation (not CYP450-dependent) and is eliminated primarily through biliary/fecal excretion, making it suitable for patients with mild to moderate renal impairment without dose adjustment. AAS Cycle - Cardiac Protection 40-80 mg/day Once daily Oral Mild Hypertension / Preventive Use 20-40 mg/day Standard Hypertension Treatment

Source: peptide-db.com ↗
Side effects

Common Side Effects

Headache Nausea or mild gastrointestinal discomfort Hot flashes or flushing Mood changes (irritability or emotional sensitivity) Fatigue during initial adjustment

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides